Evidence map›Paper›PMID 35058209›Full record

ArticleSLAS technology2022

Sorting single-cell microcarriers using commercial flow cytometers.

Joseph de Rutte, Robert Dimatteo, Sheldon Zhu, Maani M Archang, Dino Di Carlo

Open access · diamondAbstract read
In one paragraph

Article in SLAS technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Lab on a Particle Technologies.Analytical chemistry · 2024
    Review
  10. Defining T cell receptor repertoires using nanovial-based binding and functional screening.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Joseph de RutteDepartment of Bioengineering, University of California, Los Angeles, United States; Partillion Bioscience Corporation, Los Angeles, CA, United States. Electronic address: joe@partillion.com.
Robert DimatteoDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, United States.
Sheldon ZhuPartillion Bioscience Corporation, Los Angeles, CA, United States.
Maani M ArchangDepartment of Bioengineering, University of California, Los Angeles, United States.
Dino Di CarloDepartment of Bioengineering, University of California, Los Angeles, United States; Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, United States; California NanoSystems Institute, University of California, Los Angeles, United States; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, United States.
University of California, Los Angeles · USCalifornia NanoSystems Institute · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
Dermatology Scientist Training ProgramT32AR071307 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MODLIN, ROBERT L · 2017 to 2021
$1.1M
Particle-drops for democratization of digital assaysR21GM126414 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DI CARLO, DINO · 2017 to 2018
$338k
Nanovials for high-throughput analysis and selection of single cells based on secreted bio-productsR43GM142252 · NIGMS · PARTILLION BIOSCIENCE CORPORATION · PI DE RUTTE, JOSEPH · 2021 to 2021
$220k
NCI NIH HHS P30 CA016042NIAID NIH HHS P30 AI028697NIAMS NIH HHS T32 AR071307NIGMS NIH HHS R21 GM126414NIGMS NIH HHS R43 GM142252NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

The scale of biological discovery is driven by the vessels in which we can perform assays and analyze results, from multi-well plates to microfluidic compartments. We report on the compatibility of sub-nanoliter single-cell containers or "nanovials" with commercial fluorescence activated cell sorters (FACS). This recent lab on a particle approach utilizes 3D structured microparticles to isolate cells and perform single-cell assays at scale with existing lab equipment. Use of flow cytometry led to detection of fluorescently labeled protein with dynamic ranges spanning 2-3 log and detection limits down to ∼10,000 molecules per nanovial, which was the lowest amount tested. Detection limits were improved compared to fluorescence microscopy measurements using a 20X objective and a cooled CMOS camera. Nanovials with diameters between 35-85 µm could also be sorted with purity from 99-93% on different commercial instruments at throughputs up to 800 events/second. Cell-loaded nanovials were found to have unique forward and side (or back) scatter signatures that enabled gating of cell-containing nanovials using scatter metrics alone. The compatibility of nanovials with widely-available commercial FACS instruments promises to democratize single-cell assays used in discovery of antibodies and cell therapies, by enabling analysis of single cells based on secreted products and leveraging the unmatched analytical capabilities of flow cytometers to sort important clones.

Indexed as

MicrofluidicsFlow CytometryFlow cytometryMicrofluidicsMicroparticlesNanovialsSingle-cell analysis

Identifiers

PMID35058209
PMCPMC9018595
OpenAlexW3216415193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.